News & Events

Press Releases

Tepha’s cutting edge technology has been a hot topic of discussion in the medical device community since the company’s inception. Please browse the database of news and press releases for the latest highlights of Tepha’s accomplishments. You may use and republish any of the press releases on this site for any legitimate media purpose as long as you reference Tepha, Inc. or the original source.

  • September 26, 2017 Galatea Surgical Soft Tissue Support Scaffold Products to be Featured At the 2017 American Society of Plastic Surgeons Meeting

    Lexington, MA (September 26, 2017) – Galatea Surgical (“Galatea”), a wholly owned subsidiary of Tepha Inc., will be a featured exhibitor at the prestigious American Society of Plastic Surgeons (“ASPS”) Meeting in Orlando, Florida October 6th–10th. A leader and innovator in the fast-growing field of regenerative scaffolds, Galatea announced that the most recent clinical experience on the Company’s GalaSHAPE™ 3D and GalaFORM™ 3D Bioresorbable Surgical Scaffolds will be presented by Dr. Bruce Van Natta, a leading plastic surgeon based in Indianapolis, Indiana. GalaFORM 3D and GalaSHAPE 3D are the first scaffold constructs to be introduced for aesthetic surgery that incorporate a three-dimensional contouring into the design of the product. The Galatea product portfolio will on display at Booth #1022.
  • September 18, 2017 Tepha Inc. Announces Regenerative Medicine Recent Developments and R & D Initiatives

    Tepha Inc., a developer and marketer of implantable medical devices based on its proprietary P4HB™ resorbable polymer technology, announced today recent developments and R & D initiatives in the field of regenerative medicine scaffolds for the repair or replacement of compromised human tissue.   Tepha is an established developer and supplier of P4HB-based resorbable mesh and suture products for plastic surgery and hernia repair.    The Company’s expanded regenerative scaffold programs, all based on Tepha’s P4HB polymer technology, are targeting unmet clinical needs in such areas as structural heart disease, urogynecology, orthopedics, and plastic surgery.
  • April 27, 2017 Tepha Inc. Subsidiary, Galatea Surgical, Announces the Launch of GalaFORM™ 3D Surgical Scaffold

    LEXINGTON, MA, April 27, 2017 – Galatea Surgical, a wholly owned subsidiary of Tepha Inc., announced today the FDA 510k clearance of its GalaFORM™ 3D Surgical Scaffold (“GalaFORM 3D”) for use in plastic and reconstructive surgery.  Based on Tepha’s proprietary P4HB™ bioresorbable polymer technology, GalaFORM 3D is the only 3-dimensionally contoured, surgical scaffold with a reinforcing rim, designed to uplift the body’s natural shape, provide easier placement and reduce procedure time. Galatea is a Premier Partner of the American Society for Aesthetic Plastic Surgery (ASAPS), and will commercially launch GalaFORM 3D at the upcoming 50th Anniversary meeting of ASAPS in San Diego, California. 
  • March 29, 2017 Tepha Inc. Subsidiary, Galatea Surgical, Announces Launch of GalaSHAPE™ 3D Surgical Scaffold 

    LEXINGTON, MA, March 29, 2017 – Galatea Surgical, a wholly owned subsidiary of Tepha Inc., announced today the launch of its GalaSHAPE™ 3D Surgical Scaffold (“GalaSHAPE 3D”) for use in aesthetic plastic surgery.  Based on Tepha’s proprietary P4HB™ bioresorbable polymer technology, GalaSHAPE 3D is an implantable mesh device that is contoured to facilitate surgical placement in the naturally-curved areas of the human body.  The full launch of GalaSHAPE 3D follows its FDA 510(k) clearance in the fall of 2016.
  • November 15th , 2016 Tepha Inc. Subsidiary, Galatea Surgical, Announces Presentation of GalaFLEX™ Surgical Scaffold Clinical Data at London Breast Meeting

    LEXINGTON, MA, November 15th,  2016 – Galatea Surgical, a wholly owned subsidiary of Tepha, Inc. focused on the Plastic and Aesthetic surgery market, announced today that clinical data supporting the use of its GalaFLEX™ Surgical Scaffold for mastopexy (i.e. breast lift) was presented at the London Breast Meeting by William P. Adams, MD of Dallas Texas.  Galatea also announced that the first surgical procedure utilizing GalaFLEX for an aesthetic breast surgical procedure outside the United States was performed by Patrick Mallucci, MD, FRCS, a leading London-based Plastic Surgeon.  The GalaFLEX Surgical Scaffold is made from a resorbable polymer called P4HB™, developed by Galatea’s parent company, Tepha, Inc. 
  • August 31st 2016 TEPHA, Inc. Announces Buy-Out of its Royalty Obligation to Metabolix, Inc.

    TEPHA Inc, the pioneer developer of implantable medical devices based on a resorbable polymer known as poly-4-hydroxybutyrate (P4HB), announced today that the Company has completed a buy-out of its royalty obligation to its former licensor and parent company, Metabolix, Inc.  Beginning in 2008, Tepha and its partners have commercialized implantable medical devices manufactured from P4HB in both the US and Europe. Tepha’s commercial partners include, C.R. Bard Inc., B Braun, Wright Medical Group NV, and Galatea Surgical, a wholly owned subsidiary of Tepha focused on the Aesthetic Plastic Surgery market.
  • May 1, 2009. TEPHA PARTNER LAUNCHES NOVEL MONOFILAMENT ABSORBABLE SUTURE UTILIZING TEPHA’s PROPRIETARY BIOMATERIAL

    Tepha Corporate Partner, Aesculap AG, Introduces MonoMax® Monofilament Suture at the German Surgical Congress in Munich following Receipt of CE Mark.
  • July 24, 2008. Tepha Announces Appointment of John Hartnett as Executive Vice President and Chief Operating Officer

    Tepha, Inc., a developer of medical devices derived from a new class of resorbable polymers, announced today that it has appointed John Hartnett to the new position of Executive Vice President and Chief Operating Officer.
  • April 17, 2008. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers

    Tepha, Inc., a developer of medical devices derived from a new class of polymers, announced today that two of its corporate partners, Aesculap and Tornier, are conducting initial clinical evaluations of the Company's new TephaFLEX® suture products. These clinical evaluations, conducted in both the United States and Europe, represent the first human usage of medical devices derived from Tepha's new class of resorbable polymers called polyhydroxyalkanoates ("PHA's").
  • June 6, 2007. Tepha, Inc. Announces $10.7 Million Venture Capital Financing

    Tepha, Inc., a privately held medical device company, today announced that it had closed a $10.7 million financing led by The Vertical Group. Also participating in the financing were Integra Ventures, Novartis Venture Fund, and Westfield Life Sciences Fund. The funds will be used to support the further development of Tepha's unique biopolymer technology platform including materials processing, device testing, and regulatory submissions.
  • Apr 2, 2007. Tepha, Inc. Receives FDA Clearance for First Medical Device Derived from New Class of Biopolymers

    Tepha, Inc., a privately held medical device company, today announced that the FDA has cleared its TephaFLEX® Absorbable Suture product for marketing in the U.S. The TephaFLEX Absorbable Suture is the first medical device derived from a new class of biopolymers that is the product of patented recombinant DNA technology developed by Tepha and the Massachusetts Institute of Technology (MIT).
  • November 22, 2004. Tepha, Inc. Closes $4.3 Million Financing

    Tepha, Inc., a privately held Boston-area medical device company, today announced that it has closed a $4.3 million financing led by The Vertical Group. Also participating in the financing were Integra Ventures, and Novartis Venture Fund. The funds will be used to complete the submissions of Premarket Notification 510(k) Applications to the FDA for the Company’s first products, as well as for research and development and working capital.
  • Tepha, Inc., a privately-held Boston-area medical device company, announces the accomplishment of submission of a Device Master File (DMF) to the United States Food and Drug Administration (FDA) in December 2003 for its polyhydroxyalkanoate (PHA) copolymer, TephELAST™ biomaterial, a.k.a. PHA 3444.

    Tepha, Inc., a privately-held Boston-area medical device company, announces the accomplishment of submission of a Device Master File (DMF) to the United States Food and Drug Administration (FDA) in December 2003 for its polyhydroxyalkanoate (PHA) copolymer, TephELAST™ biomaterial, a.k.a. PHA 3444.